

11098

1624

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/877,387
		Filing Date	June 7, 2001
		First Named Inventor	David S. JONES
		Art Unit	1624
		Examiner Name	R. Raymond
Total Number of Pages in This Submission	16 + 92 Refs	Attorney Docket Number	252312007500

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form + duplicate for fee processing (2 pages) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement, Supplemental (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 + copy (10 pages) Ninety-two (92) References (in 3 volumes) Return Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Rebecca Shortle - 47,083
Signature	
Date	February 10, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: 2/10/04	Signature: Carolyn G. McKubre (Carolyn G. McKubre)



PATENT
Docket No. 252312007500

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 10, 2004.

Carolyn McKubre

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David S. JONES

Serial No.: 09/877,387

Filing Date: June 7, 2001

For: MULTIVALENT PLATFORM
MOLECULES COMPRISING HIGH
MOLECULAR WEIGHT
POLYETHYLENE OXIDE

Examiner: R. Raymond

Group Art Unit: 1624

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

02/17/2004 HUUONG1 00000022 031952 09877387

01 FC:1806 180.00 DA

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does


not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 252312007500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 10, 2004

Respectfully submitted,

By:


Rebecca Shortle
Registration No. 47,083

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5654
Facsimile: (650) 494-0792

FEB 13 2004

PTO/SB/08 (2-92)

Sheet 1 of 5

Form PTO/SB-1449

Docket Number 252312007500

Application Number 09/877,387

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David S. JONES

Filing Date June 7, 2001

Group Art Unit 1624

Mailing Date February 10, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/27/2002	2002/0082400	Coutts et al.			
	2.	08/08/2002	2002/0107389	Coutts et al.			
	3.	01/23/2003	2003/0018190	Jones			
	4.	08/28/2003	2003/0162953	Coutts et al.			
	5.	12/21/1965	3,225,063	D'Alelio			
	6.	05/17/1977	4,024,222	Ts'o et al.			
	7.	09/02/1980	4,220,565	Katz			
	8.	09/15/1981	4,289,872	Denkewalter et al.			
	9.	09/14/1982	4,349,538	Levy			
	10.	04/26/1983	4,381,239	Chibata et al.			
	11.	06/14/1983	4,388,441	Katz			
	12.	11/15/1983	4,415,590	Gerzon			
	13.	03/17/1987	4,650,675	Borel et al.			
	14.	06/02/1987	4,670,558	Ebel et al.			
	15.	03/15/1988	4,731,373	Barner et al.			
	16.	02/28/1989	4,808,705	Ferris			
	17.	09/05/1989	4,863,713	Goodwin et al.			
	18.	05/08/1990	4,923,985	Gansow et al.			
	19.	06/12/1990	4,933,288	Greenfield			
	20.	01/01/1991	4,981,979	Sivam			
	21.	01/22/1991	4,987,130	Tsushima et al.			
	22.	07/14/1992	5,130,116	Woo et al.			
	23.	02/09/1993	5,185,433	Dean et al.			
	24.	11/23/1993	5,264,209	Mikayama et al.			
	25.	01/11/1994	5,278,051	Seeman et al.			
	26.	03/29/1994	5,298,403	Danielson et al.			
	27.	12/06/1994	5,370,871	Dintzis et al.			

EXAMINER:


DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

pa- 841299



Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 252312007500

Application Number 09/877,387

Applicant

David S. JONES

Filing Date June 7, 2001

Group Art Unit 1624

Mailing Date February 10, 2004

	28.	01/31/1995	5,386,020	Seeman et al.			
	29.	06/18/1996	5,527,524	Tomalia et al.			
	30.	09/02/1997	5,563,395	Gobel et al.			
	31.	12/23/1997	5,700,919	Seliger et al.			
	32.	05/05/1998	5,747,244	Sheridan et al.			
	33.	01/23/2001	6,177,414	Tomalia et al.			
	34.	03/27/2001	6,207,160	Victoria et al.			
	35.	01/22/2002	6,340,460	Dintzis et al.			
	36.	04/23/2002	6,375,951	Dintzis et al.			


FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	37.	09/30/1991	CA 2,079,109	Canada				
	38.	05/08/1991	DE 3 937 116	Germany			Abstract	
	39.	07/10/1985	EP 0 147 768	Europe			Abstract	
	40.	02/14/1990	EP 0 354 323	Europe				
	41.	11/28/1990	EP 0 399 330	Europe			Abstract	
	42.	07/29/1992	EP 0 496 074	Europe				
	43.	10/28/1992	EP 0 510 356	Europe				
	44.	02/07/1991	JP 3-500530	Japan			Abstract	
	45.	01/11/1991	JP 3-5495	Japan			Abstract	
	46.	08/07/1992	JP 4-218000	Japan			Abstract	
	47.	07/13/1993	JP 5-172814	Japan			Abstract	
	48.	07/22/1993	JP 5-504761	Japan			Abstract	
	49.	08/19/1993	JP 5-505520	Japan			Abstract	
	50.	02/17/1986	JP 61-033195	Japan			Abstract	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312007500	Application Number 09/877,387
	Applicant David S. JONES	
	Filing Date June 7, 2001	Group Art Unit 1624
	Mailing Date February 10, 2004	

	51.	12/17/1987	JP 62-503171	Japan			Abstract	
	52.	01/11/1988	JP 63-005033	Japan			Abstract	
	53.	08/29/1985	WO 85/03704	WIPO				
	54.	07/17/1986	WO 86/04093	WIPO				
	55.	05/07/1987	WO 87/02777	WIPO				
	56.	10/19/1989	WO 89/09628	WIPO				
	57.	12/14/1989	WO 89/12060	WIPO				
	58.	06/27/1991	WO 91/08753	WIPO				
	59.	02/20/1992	WO 92/02531	WIPO				
	60.	07/09/1992	WO 92/11029	WIPO				
	61.	06/24/1993	WO 93/12145	WIPO				

OTHER DOCUMENTS*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	62.	Agrawal, S. et al. (1986). "Efficient Methods for Attaching Non-Radioactive Labels to the 5' Ends of Synthetic Oligodeoxyribonucleotides," <i>Nucl. Acids Res.</i> 14(15):6227-6245.
	63.	Asseline, U. and Thuong, N.T. (1990). "New Solid-Phase for Automated Synthesis of Oligonucleotides Containing an Amino-Alkyl Linker at Their 3'-End," <i>Tetrahedron Letts.</i> 31(1):81-84.
	64.	Borel, H. and Borel, Y. (1990). "A Novel Technique to Link Either Proteins or Peptides to Gammaglobulin to Construct Tolerogens," <i>J. Immunol. Methods</i> 126:159-168.
	65.	Borel, H. et al. (1986). "A Possible New Therapy of Systemic Lupus Erythematosus (SLE)," <i>Ann. N.Y. Acad. Sci.</i> 475:296-306.
	66.	Borel, H. et al. (1984). "Conjugation of DNA Fragments to Protein Carriers by Glutaraldehyde: Immunogenicity of Oligonucleotide-Hemocyanin Conjugates," <i>Journal of Immunological Methods</i> 67:289-302.
	67.	Borel, Y. and Borel, H. (1988). "Oligonucleotide Linked to Human Gammaglobulin Specifically Diminishes Anti-DNA Antibody Formation in Cultured Lymphoid Cells from Patients with Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> 82:1901-1907.
	68.	Borel, Y. et al. (1973). "Prevention of Murine Lupus Nephritis by Carrier-Dependent Induction of Immunologic Tolerance to Denatured DNA," <i>Science</i> 182:76-78.

EXAMINER:**DATE CONSIDERED:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 252312007500	Application Number 09/877,387
	Applicant David S. JONES	
	Filing Date June 7, 2001	Group Art Unit 1624
	Mailing Date February 10, 2004	

69.	Brask, J. and Jensen, K.J. (2001). "Carboproteins: A 4- α -Helix Bundle Protein Model Assembled on a D-Galactopyranoside Template," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:697-700.
70.	Clark, A.J. et al. (2001). "A Nonisocyanate Route to Monodisperse Branched Polyurethanes," <i>J. Org. Chem.</i> 66:8687-8689.
71.	Conrad, M.J. and Coutts, S. (1991). "Conjugates of Stable Polymer and Polynucleotide - Tolerogens for Human Systemic Lupus Erythematosus," Derwents Database record for European Patent No. EP 0 438 259, July 1991.
72.	Dintzis, R.Z. et al. (1985). "Inhibition of Anti-DNP Antibody Formation by High Doses of DNP-Polyacrylamide Molecules; Effects of Hapten Density and Hapten Valence," <i>J. Immunol.</i> 135(1):423-427.
73.	Dreef, C.E. et al. (1988). "Synthesis of 1-O-(1, 2-DI-O-Palmitoyl-SN-Glycero-3-Phospho)-D-MYO-Inositol 4, 5-Bisphosphate: An Analogue of Naturally Occurring (Ptd)Ins(4,5)P ₂ ," <i>Tetrahedron Letts.</i> 29(49):6513-6516.
74.	Eshhar, Z. et al. (1975). "Induction of Tolerance to Nucleic Acid Determinants by Administration of a Complex of Nucleoside D-Glutamic Acid and D-Lysine (D-GL)," <i>J. Immunol.</i> 144(2):872-876.
75.	Frenkel, G.D. et al. (1987). "Inhibition of RNA and DNA Polymerases by the Product of the Reaction of Selenite with Sulfhydryl Compounds," <i>Mol. Pharm.</i> 31(1):112-116.
76.	Gupta, K.C. et al. (October 28, 1991). "A General Method for the Synthesis of 3'-Sulfhydryl and Phosphate Group Containing Oligonucleotides," <i>Chem. Abstracts</i> 115(17):976. Abstract No. 183758p.
77.	King, T.P. et al. (1993). "Structure-Immunogenicity Relationship of Melittin and Its N-Terminal Truncated Analogs," <i>Biochemistry</i> 32(13):3506-3510.
78.	Kremsky, J.N. et al. (1987). "Immobilization of DNA via Oligonucleotides Containing an Aldehyde or Carboxylic Acid Group at the 5' Terminus," <i>Nucl. Acids. Res.</i> 15:2891-2909.
79.	Kuo, J. et al. (1991). "Chemical Modification of Hyaluronic Acid by Carbodiimides," <i>Bioconjugate Chem.</i> 2(4):232-241.
80.	Leonetti, J.P. (1988). "Antiviral Activity of Conjugates Between Poly(l-lysine) and Synthetic Oligodeoxyribonucleotides," <i>Gene</i> 72:323-332.
81.	McMurry, T.J. et al. (1992). "Convenient Sythesis of Bifunctional Tetraaza Macrocycles," <i>Bioconjugate Chem.</i> 3(2):108-117.
82.	Mitsuo, N. et al. (1978). "Permeability of Liposomal Membranes Composed of Unnatural Types of Synthetic Lecithin-Analogues," <i>Chem. Pharm. Bull.</i> 26(5):1501-1504.
83.	Nossal, G.J.V. (1989). "Immunologic Tolerance: Collaboration Between Antigen and Lymphokines," <i>Science</i> 245(4914):147-153.
84.	Papalian, M. et al. (1980). "Reaction of Systemic Lupus Erythematosus Antinative DNA Antibodies with Native DNA Fragments from 20 to 1,200 Base Pairs," <i>J. Clin. Invest.</i> 65:469-477.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FEB 13 2004

PTO/SB/08 (2-92)

Sheet 5 of 5

Form PTO-1449

Docket Number 252312007500

Application Number 09/877,387

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David S. JONES

Filing Date June 7, 2001

Group Art Unit 1624

Mailing Date February 10, 2004

- | | |
|-----|--|
| 85. | Parker, L.P. et al. (1974). "Modification of NZB/NZW F Autoimmune Disease by Development of Tolerance to DNA," <i>J. Immunol.</i> 113(1):292-297. |
| 86. | Sasaki, T. et al. (1982). "Induction of Immunological Tolerance to Single-Stranded and Double-Stranded DNA," <i>Scand. J. Immunol.</i> 16:191-200. |
| 87. | Sehon, A.H. (1982). "Suppression of IgE Antibody Responses with Tolerogenic Conjugates of Allergens and Haptens," <i>Prog. Allergy</i> 32:161-202. |
| 88. | Stollar, B.D. and Papalian, M. (1980). "Secondary Structure in Denatured DNA is Responsible for its Reaction with Antinative DNA Antibodies of Systemic Lupus Erythematosus Sera," <i>J. Clin. Invest.</i> 66:210-219. |
| 89. | Usman, N. et al. (1988). "Preparation of Glyceronucleoside Phosphoramidite Synthons and Their Use in the Solid Phase Synthesis of Acyclic Oligonucleotides," <i>Tetrahedron Letts.</i> 29(38):4831-4834. |
| 90. | Vercruysse, K.P. et al. (1997). "Synthesis and in Vitro Degradation of New Polyvalent Hydrazide Cross-Linked Hydrogels of Hyaluronic Acid," <i>Bioconjugate Chem.</i> 8:686-694. |
| 91. | Verkade, P.E. et al. (1940). "Synthesen von Glyceriden mit Hilfe von Tritylverbindungen IV," <i>Recl. Trav. Pays-Bas</i> 59:1123-1140. |
| 92. | Wilkinson, I. et al. (1987). "Tolerance Induction in Mice by Conjugates of Monoclonal Immunoglobulins and Monomethoxypolyethylene Glycol," <i>J. Immunol.</i> 139:326-331. |


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)
pa- 841299

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



PTO/SB/17 (10-03)

Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003, Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number	09/877,387
Filing Date	June 7, 2001
First Named Inventor	David S. JONES
Examiner Name	R. Raymond
Art Unit	1624
Attorney Docket No.	252312007500

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:

Deposit Account Number

03-1952

Deposit Account Name

Morrison & Foerster LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION** (continued)**3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180.00

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims	Fee from below		Fee Paid
Total Claims	95	-95** =	0	9	0.00
Independent Claims	14	-14** =	0	43	0.00
Multiple Dependent				145	0.00

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	86	2201	43	Independent claims in excess of 3	
1203	290	2203	145	Multiple dependent claim, if not paid	
1204	86	2204	43	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$) 0.00

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY

Name (Print/Type) Rebecca Shortle

Registration No. (Attorney/Agent)

47,083

(Complete if applicable)

Telephone (650) 813-5654

Signature

Date February 10, 2004